Press Release
Results of Extraordinary General Meeting held on 16 April 2007
Shire plc (LSE: SHP.L; NASDAQ: SHPGY; TSX: SHQ) ("Shire" or the "Company") announced today that its shareholders approved the proposed acquisition of New River Pharmaceuticals Inc. (NASDAQ: NRPH) ("New River") at the Shire Extraordinary General Meeting held on 16 April 2007. The approval by Shire’s shareholders satisfies one of the conditions to the tender offer by Shire’s wholly owned subsidiary for all outstanding shares of New River common stock at a price of .00 per share, or approximately .6 billion in total for the fully diluted equity interest of New River. Consummation of the tender offer now remains subject only to certain customary conditions, including the valid tender of a majority of the outstanding New River shares on a fully diluted basis.
The tender offer will expire at 12:00 Midnight, New York City time, on Tuesday, April 17, 2007. The tender offer is being made pursuant to the previously announced agreement of merger among Shire, its wholly owned subsidiary and New River.
At the Extraordinary General Meeting, a resolution to approve the New River acquisition and to sanction an increase in the total borrowings of the Shire group of companies.
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
